Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 7/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 8/20 | 0.61 |
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542462 | 1.00 | HDAC1 (0.64) | HDAC1HDAC2HTTCYP3A4LMNA | |
| SCHEMBL29407252 | 1.00 | HDAC1 (0.64) | HDAC1HDAC2HTTCYP3A4LMNA | |
| SCHEMBL10836915 | 0.88 | HTT (0.71) | HDAC1HDAC2HTTCYP3A4LMNA | |
| SCHEMBL5066429 | 0.85 | HTT (0.78) | HDAC1HDAC2HTTCYP3A4LMNA | |
| SCHEMBL5177317 | 0.85 | HTT (0.78) | HDAC1HDAC2HTTCYP3A4LMNA | |
| SCHEMBL28860002 | 0.85 | HTT (0.78) | HDAC1HDAC2HTTCYP3A4LMNA | |
| SCHEMBL3806903 | 0.84 | HTT (0.80) | HDAC1HDAC2HTTCYP3A4LMNA | |
| SCHEMBL10344722 | 0.83 | HTT (0.69) | HDAC1HDAC2HTTCYP3A4LMNA | |
| Hydrochloric Acid SCHEMBL30610402 | 0.83 | HTT (0.74) | HDAC1HDAC2HTTCYP3A4LMNA | |
| SCHEMBL796517 | 0.82 | HTT (0.82) | HDAC1HDAC2HTTCYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3419665-B1 | TREATMENT METHODS FOR FIBROSIS TARGETING SMOC2 | BRIGHAM & WOMENS HOSPITAL INC (US) | 2024-10-30 | — | — | EP | claimed |
| EP-0957926-B1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS INC (US) | 2005-02-16 | — | — | EP | claimed |
| US-20250368987-A1 | COMPOSITION COMPRISING TAF10 INHIBITOR FOR PREVENTING OR TREATING COLORECTAL CANCER | KOREA ADVANCED INST SCI & TECH (KR) | 2025-12-04 | — | — | US | disclosed |
| US-20250302863-A1 | USE OF THBS1 INHIBITOR FOR OVERCOMING DRUG RESISTANCE IN CANCER | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-10-02 | — | — | US | disclosed |
| US-20250275921-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING LIPID NANOPARTICLES | EnhancedBio Inc. (KR) | 2025-09-04 | — | — | US | disclosed |
| US-20250235446-A1 | COMPOSITION FOR INHIBITING METASTASIS AND ENHANCING ANTICANCER DRUG SENSITIVITY | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-07-24 | — | — | US | disclosed |
| US-20250223595-A1 | METHOD FOR CONSTRUCTING GENE NETWORK THROUGH SINGLE-CELL TRANSCRIPTOME AND METHOD FOR DISCOVERING KEY GENE IN DIFFERENTIATION USING SAME | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-07-10 | — | — | US | disclosed |
| WO-2025137143-A2 | COMPOSITIONS FOR MODULATING CD33 EXPRESSION | APERTURE THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-20250179500-A1 | PHARMACEUTICAL COMPOSITION COMPRISING SETMAR INHIBITOR FOR PREVENTING OR TREATING CANCER | KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2025-06-05 | — | — | US | disclosed |
| EP-4559526-A2 | COMPOSITION FOR REGULATING CANCER CELL DIVISION OR DIFFERENTIATION COMPRISING SETDB1 OR A SETDB1 INHIBITOR | Korea Advanced Institute of Science and Technology (KR) | 2025-05-28 | — | — | EP | disclosed |
| WO-2025084323-A1 | METHOD FOR INDUCING MYOCARDIAL REGENERATION | 国立研究開発法人国立循環器病研究センター | 2025-04-24 | — | — | WO | disclosed |
| WO-2011055888-A1 | NANOPARTICLE-BASED GENE DELIVERY SYSTEMS | CHUNG-ANG UNIVERSITY INDUSTRY-ACADEMY COOPERATION FOUNDTION (KR) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010147274-A1 | SECRETORY GRANULES AND GRANULOGENIC FACTORS AS A TARGET FOR CANCER TREATMENT | INHA-INDUSTRY PARTNERSHIP INSTITUTE (KR) | 2010-12-23 | — | — | WO | disclosed |
| EP-1957526-A4 | MOLECULES INHIBITION INTERCELLULAR ADHESION | ISU ABXIS CO LTD (KR) | 2009-03-11 | — | — | EP | disclosed |
| EP-1957526-A1 | MOLECULES INHIBITION INTERCELLULAR ADHESION | Isu Abxis Co., Ltd. (KR) | 2008-08-20 | — | — | EP | disclosed |
| WO-2006068398-A1 | MOLECULES INHIBITION INTERCELLULAR ADHESION | ISU ABXIS CO., LTD. (KR) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006054839-A1 | REGULATION OF PROCASPASE-2 ACTIVATION BY PHOSPHORYLATION OF PROCASPASE-2 | ATGEN CO., LTD. (KR) | 2006-05-26 | — | — | WO | disclosed |
| EP-1035870-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEPATITIS C VIRUS-ASSOCIATED DISEASES | ISIS PHARMACEUTICALS INC (US) | 2005-02-23 | — | — | EP | disclosed |
| WO-1990006312-A1 | 2',3'-DIDEOXYRIBOFURANOSIDES AND PROCESS FOR PRODUCING THEM | INSTITUT FÜR MOLEKULARBIOLOGIE UND ANALYTIK (IMA) GMBH (DE) | 1990-06-14 | — | — | WO | disclosed |
| EP-0051213-A1 | Homogeneous specific binding assay device, method for preparing it and analytical method using the device | MILES LABORATORIES, INC. (US) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275921-A1 | COMPOSITION FOR PREVENTING OR TREATING CANCER, CONTAINING LIPID NANOPARTICLES | PLIN3, TSG101, PLIN1 | HDAC1 368/4885HDAC2 1092/4885HTT 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.